Panic disorder: The place of benzodiazepines and selective serotonin reuptake inhibitors

European Neuropsychopharmacology

Volumn 11, Issue 4, 2001, Pages 307-321

  Kasper, Siegfried ^a   Resinger, Eva ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anxiety; Benzodiazepine; Depression; Panic disorder; Selective serotonin reuptake inhibitor

Indexed keywords

4 AMINOBUTYRIC ACID; ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; LORAZEPAM; MOCLOBEMIDE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AMNESIA; ANTICIPATION; ANXIETY; ANXIETY NEUROSIS; COGNITIVE THERAPY; DEPRESSION; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAINTENANCE THERAPY; NERVOUSNESS; PANIC; PHOBIA; PREVALENCE; PRIORITY JOURNAL; RELAPSE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; WITHDRAWAL SYNDROME;

EID: 0034856710     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(01)00100-6     Document Type: Article

References (101)

1. Outcome of panic disorder with or without concomitant depression: A 2-year prospective follow up study
2. Practice guideline for the treatment of patients with panic disorder
3. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study
4. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder
5. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment
6. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder
7. Consensus Statement on Panic Disorder from the International Consensus Group on Depression and Anxiety
8. Long-term pharmacologic treatment of panic disorder
9. Medication discontinuation in panic disorder
10. Panic disorder: efficacy of current treatments
11. Association of road-traffic accidents with benzodiazepine use
12. Clonazepam in the treatment of panic-disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response
13. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder
14. Period prevalence of psychiatric disorders in Edmonton
15. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis
16. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications
17. Major depression in panic disorder
18. Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine
19. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam
20. Secondary depression and anxiety neurosis
21. A meta-analysis of treatments for panic disorder
22. A meta-analysis of treatment for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure
23. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo
24. Maintenance therapy of panic disorder
25. Critique: 5-HT and mechanisms of defence
26. Secondary depression and anxiety disorders
27. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin
28. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study
29. Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder
30. The Galway study of panic disorder. I. Clomipramine and lofepramine in DSM-III-R panic disorder: a placebo controlled trial
31. Sertraline as a treatment for panic disorder
32. Neuroanatomical hypothesis of panic disorder, revised
33. An open trial of fluoxetine in the treatment of panic attacks
34. Brain defence systems and anxiety
35. Newer antidepressants and the discontinuation syndrome
36. The dependence potential of short half-life benzodiazepines: a meta-analysis
37. A multicentre, double blind, placebo-controlled study of fluvoxamine in the treatment of panic disorder
38. Effect of fluvoxamine on panic disorder
39. Long-term treatment of panic disorder with fluvoxamine in outpatients who had completed double blind studies
40. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders
41. Panic disorder, comorbidity, and suicide attempts
42. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature
43. The long-term efficacy and safety of paroxetine in panic disorder
44. Behavioral indications for serotonin receptor hypersensitivity in panic disorder
45. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States
46. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine
47. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder
48. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder
49. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial
50. A naturalistic 6-year follow-up study of patients with panic disorder
51. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder
52. Secondary depression in panic disorder and agoraphobia. I: frequency, severity, and response to treatment
53. Sertraline in the treatment of panic disorder
54. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg and placebo in panic disorder
55. Decreased brain GABA (A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study
56. Quality of life in panic disorder
57. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo
58. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine
59. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial
60. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks
61. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder
62. Diazepam versus alprazolam for the treatment of panic disorder
63. Environmental factors related to the outcome of panic disorder. A seven-year follow-up study
64. Alprazolam in panic disorder a agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety
65. A withdrawal syndrome after abrupt discontinuation of alprazolam
66. Neurobiological mechanisms in generalised anxiety disorder
67. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study
68. Clomipramine treatment of panic disorder: pros and cons
69. A double-blind, placebo-controlled, multicentre study with alprazolam and extended-release alprazolam in the treatment of panic disorder
70. Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study
71. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III: discontinuation effects
72. Discontinuation reactions to alprazolam in panic disorder
73. Sertraline in the treatment of panic disorder: a double-blind multicenter trial
74. Sertraline in the treatment of panic disorder
75. Methodologies and outcomes from the sertraline multicenter flexible-dose trials
76. One month prevalence of mental disorders in the United States based on five Epidemiologic Catchment Area sites
77. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose response study of efficacy, safety, and discontinuance
78. Reduced benzodiazepine sensitivity in panic disorder
79. Lifetime panic-depression comorbidity in the National Comorbidity Survey
80. Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse
81. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine
82. Fluoxetine in panic disorder
83. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder
84. Lorazepam vs. alprazolam in the treatment of panic disorder
85. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled, comparison of alprazolam and imipramine
86. The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies
87. Psychological strategies for discontinuing benzodiazepine treatment
88. GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: a mechanism for modulation of sensory inputs related to fear conditioning
89. Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder
90. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder
91. Moclobemide and fluoxetine for panic disorder
92. Raphe nuclei and the serotonergic system
93. International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997
94. Response of panic disorder to fixed doses of alprazolam or imipramine
95. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments
96. Outcome of panic and depression in a seven-year follow-up: results of the Zurich study
97. The effect of citalopram in panic disorder
98. Panic disorder: Impact on quality of life
99. Epidemiology of panic attacks and panic disorders